There are 2789 resources available
1088P - Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)
Presenter: Jose Luis Manzano
Session: ePoster Display
1089TiP - Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma
Presenter: Aurelio Boerlin
Session: ePoster Display
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
992P - Pan-cancer T-cell priming transcriptomic markers reveals interpatient immunomic heterogeneity independent of histologic type
Presenter: Hirotakka Miyashita
Session: ePoster Display
993P - Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
Presenter: Saulo Silva
Session: ePoster Display
994P - PCR-based analysis of PD-L1 RNA expression in lung cancer: Comparison with commonly utilized immunohistochemical assays
Presenter: Evgeny Imyanitov
Session: ePoster Display
995P - A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy
Presenter: Xiaoqian Guan
Session: ePoster Display